MELATONIN

Circadian Rhythm Sleep Disorder

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of HealthSmall moleculePhase 4 / ApprovedActive

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 54/ 100
Competitive Position: 95/ 100

Competitive context

1 Active assets in the Circadian Rhythm Sleep Disorder cohort.

Asset / Sponsor	Phase	Rating
PROPOFOL Nyree Penn	Phase 1	CC
Zolpidem Massachusetts General Hospital	N/A	D
Ramelteon Massachusetts General Hospital	N/A	D

Same molecule, other indications

MELATONIN is also rated in:

traumatic brain injuryActive

BBB

Indicative · Phase 4

74 / 100

View asset →

bipolar disorderActive

BBB

Indicative · Phase 4

72 / 100

View asset →

generalized epilepsyDormant

Indicative · Phase 4

68 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →